Human breast tumor cells are more resistant to cardiac glycoside toxicity than non-tumorigenic breast cells

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Clifford, Rebecca J ^a   Kaplan, Jack H ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BUFALIN; CARDIAC GLYCOSIDE; DIGITOXIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OUABAIN; PROTEIN TYROSINE KINASE; STAUROSPORINE;

APOPTOSIS; ARTICLE; BREAST TUMOR; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; TREATMENT DURATION; TUMOR CELL; TUMOR GROWTH;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CARDIAC GLYCOSIDES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MAMMARY GLANDS, HUMAN; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM PROTEINS; SODIUM-POTASSIUM-EXCHANGING ATPASE; SRC-FAMILY KINASES;

EID: 84892550880     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084306     Document Type: Article

References (76)

1. Schatzmann HJ (1953) Cardiac glycosides as inhibitors of active potassium and sodium transport by erythrocyte membrane. Helv Physiol Pharmacol Acta 11: 346-354. PubMed: 13142506.
2. Kaplan JH (1985) Ion movements through the sodium pump. Annu Rev Physiol 47: 535-544. doi:10.1146/annurev.ph.47.030185.002535. PubMed: 2581504.
3. Kaplan JH (2002) Biochemistry of na,K-ATPase. Annu Rev Biochem 71: 511-535. doi:10.1146/annurev.biochem.71.102201.141218. PubMed: 12045105.
4. Dvela M, Rosen H, Feldmann T, Nesher M, Lichtstein D (2007) Diverse biological responses to different cardiotonic steroids. Pathophysiology 14: 159-166. doi:10.1016/j.pathophys.2007.09.011. PubMed: 17964766.
5. Suzuki K, Taniguchi K, Iida S (1985) Ouabain binding and the conformational change in na+, K+ -ATPase. Nihon Yakurigaku Zasshi 86: 181-188. doi:10.1254/fpj.86.181. PubMed: 3002923.
6. Langer GA (1970) The role of sodium ion in the regulation of myocardial contractility. J Mol Cell Cardiol 1: 203-207. doi:10.1016/0022-2828(70)90001-5. PubMed: 4255274.
7. Xie Z, Kometiani P, Liu J, Li J, Shapiro JI et al. (1999) Intracellular reactive oxygen species mediate the linkage of Na+/K+-ATPase to hypertrophy and its marker genes in cardiac myocytes. J Biol Chem 274: 19323-19328. doi:10.1074/jbc.274.27.19323. PubMed: 10383443.
8. Rosen H, Glukhman V, Feldmann T, Fridman E, Lichtstein D (2004) Cardiac steroids induce changes in recycling of the plasma membrane in human NT2 cells. Mol Biol Cell 15: 1044-1054. PubMed: 14718569.
9. Wang Y, Qiu Q, Shen JJ, Li DD, Jiang XJ et al. (2012) Cardiac glycosides induce autophagy in human non-small cell lung cancer cells through regulation of dual signaling pathways. Int J Biochem Cell Biol 44: 1813-1824. doi:10.1016/j.biocel.2012.06.028. PubMed: 22750415.
10. Kajikawa M, Fujimoto S, Tsuura Y, Mukai E, Takeda T et al. (2002) Ouabain suppresses glucose-induced mitochondrial ATP production and insulin release by generating reactive oxygen species in pancreatic islets. Diabetes 51: 2522-2529. doi:10.2337/diabetes.51.8.2522. PubMed: 12145166.
11. Khundmiri SJ, Metzler MA, Ameen M, Amin V, Rane MJ et al. (2006) Ouabain induces cell proliferation through calcium-dependent phosphorylation of akt (protein kinase B) in opossum kidney proximal tubule cells. Am J Physiol Cell Physiol 291: C1247-C1257. doi:10.1152/ajpcell.00593.2005.
12. Aydemir-Koksoy A, Abramowitz J, Allen JC (2001) Ouabain-induced signaling and vascular smooth muscle cell proliferation. J Biol Chem 276: 46605-46611. doi:10.1074/jbc.M106178200. PubMed: 11579090.
13. Haas M, Wang H, Tian J, Xie Z (2002) Src-mediated inter-receptor cross-talk between the Na+/K+-ATPase and the epidermal growth factor receptor relays the signal from ouabain to mitogen-activated protein kinases. J Biol Chem 277: 18694-18702. doi:10.1074/jbc.M111357200. PubMed: 11907028.
14. Mohammadi K, Liu L, Tian J, Kometiani P, Xie Z et al. (2003) Positive inotropic effect of ouabain on isolated heart is accompanied by activation of signal pathways that link Na+/K+-ATPase to ERK1/2. J Cardiovasc Pharmacol 41: 609-614. doi:10.1097/00005344-200304000-00014. PubMed: 12658063.
15. Xie Z (2001) Ouabain interaction with cardiac Na/K-ATPase reveals that the enzyme can act as a pump and as a signal transducer. Cell Mol Biol 47: 383-390. PubMed: 11357899.
16. Wang Z, Zheng M, Li Z, Li R, Jia L et al. (2009) Cardiac glycosides inhibit p53 synthesis by a mechanism relieved by src or MAPK inhibition. Cancer Res 69: 6556-6564. doi:10.1158/0008-5472.CAN-09-0891. PubMed: 19679550.
17. Xu JW, Jin RM, Li EQ, Wang YR, Bai Y (2009) Signal pathways in ouabain-induced proliferation of leukemia cells. World J Pediatr 5: 140-145. doi:10.1007/s12519-009-0028-z.
18. Kennedy SG, Wagner AJ, Conzen SD, Jordán J, Bellacosa A et al. (1997) The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 11: 701-713. doi:10.1101/gad.11.6.701. PubMed: 9087425.
19. Allan LA, Morrice N, Brady S, Magee G, Pathak S et al. (2003) Inhibition of caspase-9 through phosphorylation at thr 125 by ERK MAPK. Nat Cell Biol 5: 647-654. doi:10.1038/ncb1005. PubMed: 12792650.
20. Adjei AA, Hidalgo M (2005) Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol 23: 5386-5403. doi:10.1200/JCO.2005.23.648. PubMed: 15983388.
21. Stenkvist B, Bengtsson E, Eriksson O, Holmquist J, Nordin B et al. (1979) Cardiac glycosides and breast cancer. Lancet 313: 563. doi:10.1016/S0140- 6736(79)90996-6. PubMed: 85158.
22. Stenkvist B (1999) Is digitalis a therapy for breast carcinoma? Oncol Rep 6: 493-496. PubMed: 10203580.
23. Platz EA, Yegnasubramanian S, Liu JO, Chong CR, Shim JS, et al. (2011) A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov 1: 68-77. Available online at: doi:10.1158/2159-8274.CD-10-0020
24. Haux J, Klepp O, Spigset O, Tretli S (2001) Digitoxin medication and cancer; case control and internal dose-response studies. BMC Cancer 1: 11. doi:10.1186/1471-2407-1-11. PubMed: 11532201.
25. Selby JV, Friedman GD, Fireman BH (1989) Screening prescription drugs for possible carcinogenicity: Eleven to fifteen years of follow-up. Cancer Res 49: 5736-5747. PubMed: 2571410.
26. Niraula S, Pond G, De Wit R, Eisenberger M, Tannock IF et al. (2011) Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Can Urol Assoc J: 1-8. doi:10.5489/cuaj.11013. PubMed: 2206073323671512.
27. Bernstein L, Ross RK (1992) Prior medication use and health history as risk factors for non-hodgkin's lymphoma: Preliminary results from a case-control study in Los Angeles County. Cancer Res 52: 5510s-5515s. PubMed: 1394165.
28. Friedman GD (1984) Digitalis and breast cancer. Lancet 324: 875. doi:10.1016/S0140-6736(84)90915-2. PubMed: 6148608.
29. Ewertz M, Holmberg L, Tretli S, Pedersen BV, Kristensen A (2001) Risk factors for male breast cancer - a case-control study from Scandinavia. Acta Oncol 40: 467-471. doi:10.1080/02841860117406. PubMed: 11504305.
30. Lenfant-Pejovic MH, Mlika-Cabanne N, Bouchardy C, Auquier A (1990) Risk factors for male breast cancer: A franco-swiss case-control study. Int J Cancer 45: 661-665. doi:10.1002/ijc.2910450415. PubMed: 2323842.
31. Ahern TP, Lash TL, Sørensen HT, Pedersen L (2008) Digoxin treatment is associated with an increased incidence of breast cancer: A population-based case-control study. Breast Cancer Res 10: R102. doi:10.1186/bcr2205. PubMed: 19055760.
32. Garbe JC, Bhattacharya S, Merchant B, Bassett E, Swisshelm K et al. (2009) Molecular distinctions between stasis and telomere attrition senescence barriers shown by long-term culture of normal human mammary epithelial cells. Cancer Res 69: 7557-7568. doi:10.1158/0008-5472.CAN-09-0270. PubMed: 19773443.
33. Santner SJ, Dawson PJ, Tait L, Soule HD, Eliason J et al. (2001) Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat 65: 101-110. doi:10.1023/A:1006461422273. PubMed: 11261825.
34. Imbalzano KM, Tatarkova I, Imbalzano AN, Nickerson JA (2009) Increasingly transformed MCF-10A cells have a progressively tumor-like phenotype in three-dimensional basement membrane culture. Cancer Cell Int 9: 7-2867-9-7. doi:10.1186/1475-2867-9-7. PubMed: 19291318.
35. Miller FR, Soule HD, Tait L, Pauley RJ, Wolman SR et al. (1993) Xenograft model of progressive human proliferative breast disease. J Natl Cancer Inst 85: 1725-1732. doi:10.1093/jnci/85.21.1725. PubMed: 8411256.
36. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J et al. (1987) Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47: 414-418. PubMed: 3539322.
37. Clifford RJ, Kaplan JH. (2008) {Beta}-subunit overexpression alters the stoicheometry of assembled na-K-ATPase subunits in MDCK cells. Am J Physiol Renal Physiol 295: F1314-F1323. doi:10.1152/ajprenal.90406.2008.
38. Hu YK, Kaplan JH (2000) Site-directed chemical labeling of extracellular loops in a membrane protein. the topology of the na,K-ATPase alpha -subunit. J Biol Chem 275: 19185-19191. doi:10.1074/jbc.M000641200. PubMed: 10764750.
39. Laughery MD, Todd ML, Kaplan JH (2003) Mutational analysis of {alpha}-{beta} subunit interactions in the delivery of na,K-ATPase heterodimers to the plasma membrane. J Biol Chem 278: 34794-34803. doi:10.1074/jbc. M302899200. PubMed: 12826673.
40. So JY, Lee HJ, Kramata P, Minden A, Suh N (2012) Differential expression of key signaling proteins in MCF10 cell lines, a human breast cancer progression model. Mol Cell Pharmacol 4(1): 31-40.
41. Lacroix M, Leclercq G (2004) Relevance of breast cancer cell lines as models for breast tumours: An update. Breast Cancer Res Treat 83: 249-289. Available online at: doi:10.1023/B:BREA.0000014042.54925.cc. PubMed: 14758095.
42. Dvela M, Rosen H, Ben-Ami HC, Lichtstein D. (2012) Endogenous ouabain regulates cell viability. Am J Physiol Cell Physiol 302: C442-C452. doi:10.1152/ajpcell.00336.2011.
43. Dmitrieva RI, Doris PA (2003) Ouabain is a potent promoter of growth and activator of ERK1/2 in ouabain-resistant rat renal epithelial cells. J Biol Chem 278: 28160-28166. doi:10.1074/jbc.M303768200. PubMed: 12736249.
44. Hainaut P, Hollstein M (2000) P53 and human cancer: The first ten thousand mutations. Adv Cancer Res 77: 81-137. PubMed: 10549356.
45. Dumay A, Feugeas JP, Wittmer E, Lehmann-Che J, Bertheau P et al. (2013) Distinct tumor protein p53 mutants in breast cancer subgroups. Int J Cancer 132: 1227-1231. doi:10.1002/ijc.27767. PubMed: 22886769.
46. Kometiani P, Liu L, Askari A (2005) Digitalis-induced signaling by Na +/K+-ATPase in human breast cancer cells. Mol Pharmacol 67: 929-936. doi:10.1124/mol.104.007302. PubMed: 15602003.
47. Tian J, Cai T, Yuan Z, Wang H, Liu L et al. (2006) Binding of src to Na +/K+-ATPase forms a functional signaling complex. Mol Biol Cell 17: 317-326. PubMed: 16267270.
48. Roskoski R Jr (2005) Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun 331: 1-14. doi:10.1016/j.bbrc. 2005.03.012. PubMed: 15845350.
49. Weigand KM, Swarts HG, Fedosova NU, Russel FG, Koenderink JB (1818) (2012) Na,K-ATPase activity modulates src activation: A role for ATP/ADP ratio. Biochim Biophys Acta: 1269-1273. doi:10.1016/j.bbamem.2012.01.015.
50. Matsuda H (1983) Effects of intracellular calcium injection on steady state membrane currents in isolated single ventricular cells. Pflugers Arch: 81-83. doi:10.1007/BF00585176. PubMed: 6408604.
51. Smith TW (1988) Digitalis. mechanisms of action and clinical use. N Engl J Med 318: 358-365. doi:10.1056/NEJM198802113180606. PubMed: 3277052.
52. Akera T, Ng Y. (1991) Digitalis sensitivity of na+,K+-ATPase, myocytes and the heart. Life Sci 48: 97-106.
53. Rahimtoola SH (2004) Digitalis therapy for patients in clinical heart failure. Circulation 109: 2942-2946. doi:10.1161/01.CIR.0000132477.32438.03. PubMed: 15210610.
54. Kulikov A, Eva A, Kirch U, Boldyrev A, Scheiner-Bobis G (2007) Ouabain activates signaling pathways associated with cell death in human neuroblastoma. BBA-Biomembranes 1768: 1691-1702. doi:10.1016/j.bbamem.2007.04.012.
55. Mijatovic T, Jungwirth U, Heffeter P, Hoda MAR, Dornetshuber R et al. (2009) The Na+/K+-ATPase is the achilles heel of multi-drug-resistant cancer cells. Cancer Lett 282: 30-34. doi:10.1016/j.canlet.2009.02.048. PubMed: 19339106.
56. Lingrel JB (2010) The physiological significance of the cardiotonic Steroid/Ouabain-binding site of the na,K-ATPase. Annu Rev Physiol 72: 395-412. doi:10.1146/annurev-physiol-021909-135725. PubMed: 20148682.
57. Pierre SV, Sottejeau Y, Gourbeau JM, Sanchez G, Shidyak A et al. (2008) Isoform specificity of na-K-ATPase-mediated ouabain signaling. Am J Physiol Renal Physiol 294: F859-F866. doi:10.1152/ajprenal.00089.2007.
58. Liang M, Tian J, Liu L, Pierre S, Liu J et al. (2007) Identification of a pool of non-pumping Na/K-ATPase. J Biol Chem 282: 10585-10593. doi:10.1074/jbc.M609181200. PubMed: 17296611.
59. Liu L, Ivanov AV, Gable ME, Jolivel F, Morrill GA et al. (2011) Comparative properties of caveolar and noncaveolar preparations of kidney Na+/K+-ATPase. Biochemistry 50: 8664-8673. doi:10.1021/bi2009008. PubMed: 21905705.
60. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES et al. (2009) Classification of cell death: Recommendations of the nomenclature committee on cell death 2009. Cell Death Differ 16: 3-11. doi:10.1038/cdd.2008.150. PubMed: 18846107.
61. Elbendary AA, Cirisano FD, Evans AC Jr, Davis PL, Iglehart JD et al. (1996) Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin Cancer Res 2: 1571-1575. PubMed: 9816335.
62. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC et al. (2002) The IARC TP53 database: New online mutation analysis and recommendations to users. Hum Mutat 19: 607-614. doi:10.1002/humu.10081. PubMed: 12007217.
63. Ottenhoff-Kalff AE, Rijksen G, van Beurden EACM, Hennipman A, Michels AA et al. (1992) Characterization of protein tyrosine kinases from human breast cancer: Involvement of the c-src oncogene product. Cancer Res 52: 4773-4778. PubMed: 1380891.
64. Muthuswamy SK, Siegel PM, Dankort DL, Webster MA, Muller WJ (1994) Mammary tumors expressing the neu proto-oncogene possess elevated c-src tyrosine kinase activity. Mol Cell Biol 14: 735-743. PubMed: 7903421.
65. Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D et al. (2009) Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 69: 565-572. doi:10.1158/0008-5472.CAN-08-3389. PubMed: 19147570.
66. Winnicka K, Bielawski K, Bielawska A, Miltyk W (2010) Dual effects of ouabain, digoxin and proscillaridin A on the regulation of apoptosis in human fibroblasts. Nat Prod Res 24: 274-285. doi:10.1080/14786410902991878. PubMed: 20140806.
67. Nguyen AT, Wallace DP, Blanco G (2007) Ouabain binds with high affinity to the na,K-ATPase in human polycystic kidney cells and induces extracellular Signal-Regulated kinase activation and cell proliferation. Journal of the American Society of Nephrology 18: 46-57. doi:10.1681/ASN.2006010086. PubMed: 17151336.
68. Verbeek BS, Vroom TM, Adriaansen-Slot SS, Ottenhoff-Kalff AE, Geertzema JGN et al. (1996) c-src protein expression is increased in human breast cancer. an immunohistochemical and biochemical analysis. J Pathol 180: 383-388. Available online at: doi:10.1002/(SICI)1096-9896(199612)180:4〈383:AID- PATH686〉3.0.CO;2-N.
69. Mizumoto Y, Kyo S, Mori N, Sakaguchi J, Ohno S et al. (2007) Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis. Cancer Sci 98: 652-658. doi:10.1111/j.1349-7006.2007.00445.x. PubMed: 17388789.
70. Friday BB, Adjei AA (2008) Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 14: 342-346. doi:10.1158/1078-0432.CCR-07-4790. PubMed: 18223206.
71. Cho JY, Katz DR, Chain BM (2003) Staurosporine induces rapid homotypic intercellular adhesion of U937 cells via multiple kinase activation. Br J Pharmacol 140: 269-276. doi:10.1038/sj.bjp.0705436. PubMed: 12970105.
72. Shen MR, Chou CY, Browning JA, Wilkins RJ, Ellory JC (2001) Human cervical cancer cells use Ca2+ signalling, protein tyrosine phosphorylation and MAP kinase in regulatory volume decrease. J Physiol 537: 347-362. doi:10.1111/j.1469-7793.2001.00347.x. PubMed: 11731569.
73. Chou CY, Shen MR, Wu SN (1995) Volume-sensitive chloride channels associated with human cervical carcinogenesis. Cancer Res 55: 6077-6083. PubMed: 8521396.
74. Morgan JP (1985) The effects of digitalis on intracellular calcium transients in mammalian working myocardium as detected with aequorin. J Mol Cell Cardiol 17: 1065-1075. doi:10.1016/S0022-2828(85)80122-X. PubMed: 3908693.
75. Fulda S, Gorman AM, Hori O, Samali A. (2010) Cellular stress responses: Cell survival and cell death. Int J Cell Biol 2010: 214074. doi:10.1155/2010/ 214074.
76. Bortner CD, Scoltock AB, Sifre MI, Cidlowski JA (2012) Osmotic stress resistance imparts acquired anti-apoptotic mechanisms in lymphocytes. J Biol Chem 287: 6284-6295. doi:10.1074/jbc.M111.293001. PubMed: 22228768.